Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$3.01
$4.41
$2.93
$13.53
$142.13MN/A405,931 shs830,968 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.63
-0.6%
$12.71
$5.22
$27.38
$159.87M0.43145,863 shs75,083 shs
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$5.66
+5.4%
$4.32
$1.97
$22.47
N/A1.41303,813 shs108,614 shs
Vaccitech plc stock logo
VACC
Vaccitech
$0.88
-3.3%
$1.57
$1.64
$5.10
$33.92M-0.4244,643 shs5,421 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
0.00%-8.51%-49.41%-15.69%+300,999,900.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-0.55%-0.16%-4.17%-22.42%+88.79%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
+5.40%+8.02%+14.11%+52.97%-70.05%
Vaccitech plc stock logo
VACC
Vaccitech
-3.30%-12.00%-6.78%-11.11%-47.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alumis Inc. stock logo
ALMS
Alumis
2.9206 of 5 stars
3.60.00.00.02.61.71.3
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.0735 of 5 stars
3.50.01.72.73.21.71.3
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.8819 of 5 stars
3.44.00.00.02.41.70.6
Vaccitech plc stock logo
VACC
Vaccitech
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
3.22
Buy$22.86659.37% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50141.49% Upside
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
2.71
Moderate Buy$33.83497.76% Upside
Vaccitech plc stock logo
VACC
Vaccitech
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VACC, SLN, ALMS, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$35.00
6/13/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00
6/10/2025
Alumis Inc. stock logo
ALMS
Alumis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$18.00
5/15/2025
Alumis Inc. stock logo
ALMS
Alumis
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $25.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$4.00 ➝ $3.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$45.00 ➝ $25.00
5/9/2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $35.00
4/30/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/22/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
3/26/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
3/20/2025
Alumis Inc. stock logo
ALMS
Alumis
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/A$5.51 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.88 per share14.40$2.05 per share6.16
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
$43.26MN/AN/AN/A$4.48 per shareN/A
Vaccitech plc stock logo
VACC
Vaccitech
$13.42M2.53$0.05 per share19.30$6.52 per share0.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$294.23MN/A0.00N/AN/AN/A-406.27%-107.29%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.30N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$45.31M-$1.50N/AN/AN/A-260.55%-56.17%-33.96%8/15/2025 (Estimated)
Vaccitech plc stock logo
VACC
Vaccitech
$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/A

Latest VACC, SLN, ALMS, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.47-$1.82-$0.35-$1.82N/AN/A
5/8/2025Q1 2025
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
-$0.18-$0.60-$0.42-$0.60$3.58 million$0.14 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.43%N/A26.09%3 Years
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/AN/AN/AN/AN/A
Vaccitech plc stock logo
VACC
Vaccitech
N/AN/AN/AN/AN/A

Latest VACC, SLN, ALMS, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
3.73
3.73
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
N/A
8.81
8.81
Vaccitech plc stock logo
VACC
Vaccitech
N/A
15.26
15.26

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
98.73%
Vaccitech plc stock logo
VACC
Vaccitech
26.13%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
4.10%
Vaccitech plc stock logo
VACC
Vaccitech
6.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A47.22 millionN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Silence Therapeutics PLC Sponsored ADR stock logo
SLN
Silence Therapeutics
100N/AN/ANot Optionable
Vaccitech plc stock logo
VACC
Vaccitech
3338.55 million36.23 millionNot Optionable

Recent News About These Companies

10 Startups Founded Out Of Oxford University
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024
How real are the threats to the US dollar?
Google invests in UK vaccine pioneer Vaccitech
News - Leon Hooftman

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alumis stock logo

Alumis NASDAQ:ALMS

$3.01 0.00 (0.00%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$3.12 +0.11 (+3.65%)
As of 06/18/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.63 -0.07 (-0.55%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$12.89 +0.26 (+2.05%)
As of 06/18/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Silence Therapeutics stock logo

Silence Therapeutics NASDAQ:SLN

$5.66 +0.29 (+5.40%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$5.61 -0.05 (-0.87%)
As of 06/18/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

Vaccitech stock logo

Vaccitech NASDAQ:VACC

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.